SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The Revenue for the quarter ended  December 2022 of Rs. 46457.50 millions grew by 23.21 % from Rs. 37706.60 millions.Net profit declined -5.57% to Rs. 4867.30 millions from Rs. 5154.30 millions.Operating profit for the quarter ended December 2022 rose to 10674.10 millions as compared to 9616.20 millions of corresponding quarter ended December 2021.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202212 202112 % Var 202212 202112 % Var 202203 202103 % Var
Sales 46457.50 37706.60 23.21 148639.20 115791.00 28.37 155859.80 141160.50 10.41
Other Income 746.30 3132.50 -76.18 2925.50 8092.10 -63.85 11968.80 1920.70 523.15
PBIDT 10674.10 9616.20 11.00 42709.40 25651.90 66.50 38654.40 24490.80 57.83
Interest 1308.90 854.70 53.14 3107.30 2969.10 4.65 3881.00 2675.20 45.07
PBDT 9365.20 8761.50 6.89 39602.10 21027.10 88.34 16568.10 20920.00 -20.80
Depreciation 4304.40 3552.40 21.17 11888.90 9958.10 19.39 13499.50 12364.30 9.18
PBT 5060.80 5209.10 -2.85 27713.20 11069.00 150.37 3068.60 8555.70 -64.13
TAX 193.50 54.80 253.10 597.80 -793.20 -175.37 4068.50 131.70 2989.22
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PAT 4867.30 5154.30 -5.57 27115.40 11862.20 128.59 -999.90 8424.00 -111.87
Equity 2399.30 2399.30 0.00 2399.30 2399.30 0.00 2399.30 2399.30 0.00
PBIDTM(%) 22.98 25.50 -9.91 28.73 22.15 29.70 24.80 17.35 42.95

Sun Pharma Inds. Share Price

1675.20 -17.95 (-1.06%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×